Testing an APA program to improve outcomes in large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma, or a low-grade B lymphoma that has transformed into high-grade (not other lymphoma types)
- You are 65 or older
- You are starting first-line treatment (no prior full chemotherapy for this; only limited pre-treatment is allowed)
- Your overall health is good enough to do treatment (performance status 0–2) and you can take RCHOP
- Your heart function is adequate (left heart pumping strength, LVEF, is 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.